Company intelligence / Profile preview

Neuron Bio

Ownership: Private
Development stage: Preclinical

Overview

Neuron Bio is developing novel simvastatin-related small molecules as neuroprotective agents to modify progression in Alzheimer’s disease. Their lead compound, NST0076, is being evaluated preclinically for its ability to target key pathways related to neurotrophin synthesis and neuronal survival while avoiding cholesterol-lowering side effects typical of statins. The company also develops biomarker tools for early diagnosis of CNS diseases. No clinical results have been published yet.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

4 assets

NST0037

Preclinical

3 more assets in the full pipeline.

Partnerships

Academic collaborations with Prof. Pahan and Prof. Mayor's groups

Beyond the preview

Go deeper on Neuron Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neuron Bio.